174 related articles for article (PubMed ID: 34223956)
1. Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.
Gehlen M; Schmidt N; Pfeifer M; Balasingam S; Schwarz-Eywill M; Maier A; Werner M; Siggelkow H
Calcif Tissue Int; 2021 Dec; 109(6):685-695. PubMed ID: 34223956
[TBL] [Abstract][Full Text] [Related]
2. Predictors of new fragility fractures after diagnosis of indolent systemic mastocytosis.
van der Veer E; Arends S; van der Hoek S; Versluijs JB; de Monchy JGR; Oude Elberink JNG; van Doormaal JJ
J Allergy Clin Immunol; 2014 Dec; 134(6):1413-1421. PubMed ID: 24985401
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of fractures and osteoporosis in patients with indolent systemic mastocytosis.
van der Veer E; van der Goot W; de Monchy JG; Kluin-Nelemans HC; van Doormaal JJ
Allergy; 2012 Mar; 67(3):431-8. PubMed ID: 22229787
[TBL] [Abstract][Full Text] [Related]
4. An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosis.
Riffel P; Schwaab J; Lutz C; Naumann N; Metzgeroth G; Fabarius A; Schoenberg SO; Hofmann WK; Valent P; Reiter A; Jawhar M
J Cancer Res Clin Oncol; 2020 Apr; 146(4):945-951. PubMed ID: 31980928
[TBL] [Abstract][Full Text] [Related]
5. Increased osteoblast and osteoclast indices in individuals with systemic mastocytosis.
Seitz S; Barvencik F; Koehne T; Priemel M; Pogoda P; Semler J; Minne H; Pfeiffer M; Zustin J; Püschel K; Eulenburg C; Schinke T; Amling M
Osteoporos Int; 2013 Aug; 24(8):2325-34. PubMed ID: 23436077
[TBL] [Abstract][Full Text] [Related]
6. Higher prevalence of vertebral fractures in systemic mastocytosis, but not in cutaneous mastocytosis and idiopathic mast cell activation syndrome.
Degboé Y; Eischen M; Apoil PA; Mailhol C; Dubreuil P; Hermine O; Paul C; Bulai Livideanu C; Laroche M
Osteoporos Int; 2019 Jun; 30(6):1235-1241. PubMed ID: 30847528
[TBL] [Abstract][Full Text] [Related]
7. Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis.
Rossini M; Zanotti R; Bonadonna P; Artuso A; Caruso B; Schena D; Vecchiato D; Bonifacio M; Viapiana O; Gatti D; Senna G; Riccio A; Passalacqua G; Pizzolo G; Adami S
Bone; 2011 Oct; 49(4):880-5. PubMed ID: 21782049
[TBL] [Abstract][Full Text] [Related]
8. [Severe therapy refractive osteoporosis : A rare differential diagnosis].
Gehlen M; Lazarescu AD; Hinz C; Schmidt N; Pfeifer M; Werner M; Weidemann HF; Schwarz-Eywill M; Maier A
Z Rheumatol; 2016 Sep; 75(7):729-35. PubMed ID: 27193336
[TBL] [Abstract][Full Text] [Related]
9. Systemic mastocytosis: A cohort study on clinical characteristics of 136 patients in a large tertiary centre.
Hermans MAW; Rietveld MJA; van Laar JAM; Dalm VASH; Verburg M; Pasmans SGMA; Gerth van Wijk R; van Hagen PM; van Daele PLA
Eur J Intern Med; 2016 May; 30():25-30. PubMed ID: 26809706
[TBL] [Abstract][Full Text] [Related]
10. Evolution of urticaria pigmentosa into indolent systemic mastocytosis: abnormal immunophenotype of mast cells without evidence of c-kit mutation ASP-816-VAL.
Noack F; Escribano L; Sotlar K; Nunez R; Schuetze K; Valent P; Horny HP
Leuk Lymphoma; 2003 Feb; 44(2):313-9. PubMed ID: 12688351
[TBL] [Abstract][Full Text] [Related]
11. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM.
Alvarez-Twose I; Zanotti R; González-de-Olano D; Bonadonna P; Vega A; Matito A; Sánchez-Muñoz L; Morgado JM; Perbellini O; García-Montero A; De Matteis G; Teodósio C; Rossini M; Jara-Acevedo M; Schena D; Mayado A; Zamò A; Mollejo M; Sánchez-López P; Cabañes N; Orfao A; Escribano L; ;
J Allergy Clin Immunol; 2014 Feb; 133(2):520-8. PubMed ID: 23921094
[TBL] [Abstract][Full Text] [Related]
12. Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.
Trizuljak J; Sperr WR; Nekvindová L; Elberink HO; Gleixner KV; Gorska A; Lange M; Hartmann K; Illerhaus A; Bonifacio M; Perkins C; Elena C; Malcovati L; Fortina AB; Shoumariyeh K; Jawhar M; Zanotti R; Bonadonna P; Caroppo F; Zink A; Triggiani M; Parente R; von Bubnoff N; Yavuz AS; Hägglund H; Mattsson M; Panse J; Jäkel N; Kilbertus A; Hermine O; Arock M; Fuchs D; Sabato V; Brockow K; Bretterklieber A; Niedoszytko M; van Anrooij B; Reiter A; Gotlib J; Kluin-Nelemans HC; Mayer J; Doubek M; Valent P
Allergy; 2020 Aug; 75(8):1927-1938. PubMed ID: 32108361
[TBL] [Abstract][Full Text] [Related]
13. Tryptase and histamine metabolites as diagnostic indicators of indolent systemic mastocytosis without skin lesions.
van Doormaal JJ; van der Veer E; van Voorst Vader PC; Kluin PM; Mulder AB; van der Heide S; Arends S; Kluin-Nelemans JC; Oude Elberink JN; de Monchy JG
Allergy; 2012 May; 67(5):683-90. PubMed ID: 22435702
[TBL] [Abstract][Full Text] [Related]
14. Bone involvement and osteoporosis in mastocytosis.
Rossini M; Zanotti R; Viapiana O; Tripi G; Orsolini G; Idolazzi L; Bonadonna P; Schena D; Escribano L; Adami S; Gatti D
Immunol Allergy Clin North Am; 2014 May; 34(2):383-96. PubMed ID: 24745681
[TBL] [Abstract][Full Text] [Related]
15. KIT D816V mutation burden does not correlate to clinical manifestations of indolent systemic mastocytosis.
Broesby-Olsen S; Kristensen T; Vestergaard H; Brixen K; Møller MB; Bindslev-Jensen C;
J Allergy Clin Immunol; 2013 Sep; 132(3):723-728. PubMed ID: 23587333
[TBL] [Abstract][Full Text] [Related]
16. Multimodal therapy for vertebral involvement of systemic mastocytosis.
Krüger A; Hamann C; Brendel C; Ramaswamy A; Schnabel M; Neubauer A; Hofbauer LC
Spine (Phila Pa 1976); 2009 Aug; 34(17):E626-8. PubMed ID: 19644322
[TBL] [Abstract][Full Text] [Related]
17. Fracture Risk Reduction by Bisphosphonates in Mastocytosis?
Onnes MC; van Doormaal JJ; van der Veer E; Versluijs JB; Arends S; Oude Elberink HNG
J Allergy Clin Immunol Pract; 2020; 8(10):3557-3564. PubMed ID: 32673882
[TBL] [Abstract][Full Text] [Related]
18. Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients.
Theoharides TC; Boucher W; Spear K
Int Arch Allergy Immunol; 2002 Aug; 128(4):344-50. PubMed ID: 12218373
[TBL] [Abstract][Full Text] [Related]
19. Management of a Lumbar Burst Fracture Occurring After a Sneeze in a Patient Affected by Systemic Mastocytosis: A Case Report.
De Iure F; Amendola L; Fabbri D; Chehrassan M; Corghi A; Cappuccio M
JBJS Case Connect; 2021 Aug; 11(3):. PubMed ID: 34449448
[TBL] [Abstract][Full Text] [Related]
20. Indolent systemic mastocytosis with elevated serum tryptase, absence of skin lesions, and recurrent severe anaphylactoid episodes.
Florian S; Krauth MT; Simonitsch-Klupp I; Sperr WR; Fritsche-Polanz R; Sonneck K; Födinger M; Agis H; Böhm A; Wimazal F; Horny HP; Valent P
Int Arch Allergy Immunol; 2005 Mar; 136(3):273-80. PubMed ID: 15722637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
